# CJC-1295 Ipamorelin Dosage in Research: Doses, Routes & Half-Life

> CJC-1295 Ipamorelin dosage as studied in research: the human PK doses of CJC-1295, ipamorelin's rodent dosing, routes, and half-life. Research context only — no human dosing guidance.

The doses, routes, and half-lives recorded in the published studies — described strictly as research context, never as guidance for human use.

## The short version

This page reports CJC-1295 Ipamorelin dosage the way the studies recorded it — which species got how much, by which route — and nothing more. It is not a protocol and it is not advice. Two facts shape everything here. First, the two halves run on different clocks: CJC-1295 with its DAC handle lasts days in humans, while ipamorelin lasts a couple of hours at most. Second, the human numbers come from CJC-1295's early Phase 1 pharmacokinetic studies, while almost all of ipamorelin's dosing data comes from rats — and there's no published human study of the pre-mixed combination at all. So you'll see real measured doses below, always tied to the animal or early-human study they came from, never a recommendation to use any of them.

## Cjc 1295 ipamorelin dosage: the research record

**CJC-1295 (with DAC), human PK studies.** Ascending single and multiple subcutaneous doses of 30 or 60 micrograms per kilogram were administered to healthy adults (ages 21 to 61) to characterize the multi-day GH and IGF-1 response [1]. Phase 1 work explored the 30 to 90 micrograms-per-kilogram range. In GHRH-knockout mouse studies, a 2-micrograms-per-day dose was used.

**CJC-1295 no-DAC (Mod GRF 1-29).** This short-acting form has no formal standalone human PK study; research protocols model it as a brief pulsatile GHRH signal.

**Ipamorelin (rodent).** Bone-formation work used 100 micrograms per kilogram three times daily [9]; bone-mineral-content work used 0.5 milligrams per kilogram per day for 12 weeks [10]; GI-motility studies for the ghrelin-agonist class spanned roughly 0.01 to 1 milligram per kilogram intravenously [13]. In rodent models, the GH response plateaued near 1 microgram per kilogram. No validated human PK for ipamorelin has been published.

Every figure above is reported as "studied at X in [species] by [route]" — not a human dose.

## Half-life: the mismatched clocks

CJC-1295 with DAC has a human half-life on the order of 6 to 8 days — the albumin-bound peptide stays detectable in rat plasma beyond 72 hours [5], and the human GH/IGF-1 elevation runs for days [1]. CJC-1295 without DAC (Mod GRF 1-29) is on the order of minutes to roughly 30 minutes, like native GRF(1-29), because DPP-IV cleaves it quickly. Ipamorelin clears under about 2 hours in rodent plasma, with a peak GH response near 40 minutes post-dose; no validated human half-life is published. This mismatch — a multi-day GHRH agent paired with a short-acting GHRP — is exactly why the net GH exposure of any given combination protocol is uncharacterized.

## Routes studied and handling context

Routes recorded in the literature are subcutaneous and intravenous, with continuous subcutaneous infusion (osmotic minipump) and intranasal delivery appearing in rodent PK work. On handling: lyophilized (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2 to 8 degrees Celsius and degrade over weeks via asparagine deamidation — and degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues undergo DPP-IV cleavage in plasma; CJC-1295's substitutions and DAC were engineered to resist it. This is standard laboratory-handling context, not a preparation instruction.

## What the human clinical record does and doesn't contain

CJC-1295 (DAC) reached Phase 2 before development was discontinued; a Phase 2 program ended after an adverse event in one subject reported as unrelated to the established mechanism. Phase 1 data in healthy adults characterized its PK and dose-response [1]. Ipamorelin was investigated — including a postoperative-ileus program in the ghrelin-agonist class [13] — but was not advanced to approval. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 Ipamorelin combination itself. Any dosing figure attached to the "blend" therefore comes from single-component studies, not from a trial of the combination — which is why this page reports doses only as what was administered in specific studies, and stops there.

---

A forward read of the published GH-secretagogue science — every CJC-1295 and ipamorelin finding logged to its source, the never-trialed fixed blend flagged in plain view, and no clinic, prescription, or product anywhere behind the console.